Logo image of YCBD

CBDMD INC (YCBD) Stock Fundamental Analysis

USA - NYSEARCA:YCBD - US12482W4087 - Common Stock

0.693 USD
+0 (+0.29%)
Last: 9/18/2025, 2:45:12 PM
Fundamental Rating

2

Overall YCBD gets a fundamental rating of 2 out of 10. We evaluated YCBD against 196 industry peers in the Pharmaceuticals industry. YCBD may be in some trouble as it scores bad on both profitability and health. YCBD has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year YCBD has reported negative net income.
In the past year YCBD has reported a negative cash flow from operations.
In the past 5 years YCBD reported 4 times negative net income.
In the past 5 years YCBD always reported negative operating cash flow.
YCBD Yearly Net Income VS EBIT VS OCF VS FCFYCBD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

YCBD has a Return On Assets (-38.06%) which is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -625.23%, YCBD is doing worse than 78.06% of the companies in the same industry.
Industry RankSector Rank
ROA -38.06%
ROE -625.23%
ROIC N/A
ROA(3y)-140.25%
ROA(5y)-86.1%
ROE(3y)-308.88%
ROE(5y)-187.27%
ROIC(3y)N/A
ROIC(5y)N/A
YCBD Yearly ROA, ROE, ROICYCBD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

1.3 Margins

YCBD has a Gross Margin of 62.35%. This is in the better half of the industry: YCBD outperforms 69.90% of its industry peers.
YCBD's Gross Margin has been stable in the last couple of years.
YCBD does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 62.35%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.98%
GM growth 5Y0.07%
YCBD Yearly Profit, Operating, Gross MarginsYCBD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

3

2. Health

2.1 Basic Checks

YCBD does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for YCBD has been increased compared to 1 year ago.
Compared to 5 years ago, YCBD has more shares outstanding
Compared to 1 year ago, YCBD has a worse debt to assets ratio.
YCBD Yearly Shares OutstandingYCBD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100K 200K 300K 400K
YCBD Yearly Total Debt VS Total AssetsYCBD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -22.26, we must say that YCBD is in the distress zone and has some risk of bankruptcy.
YCBD's Altman-Z score of -22.26 is on the low side compared to the rest of the industry. YCBD is outperformed by 81.12% of its industry peers.
There is no outstanding debt for YCBD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -22.26
ROIC/WACCN/A
WACC9.68%
YCBD Yearly LT Debt VS Equity VS FCFYCBD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M 80M 100M

2.3 Liquidity

A Current Ratio of 0.63 indicates that YCBD may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.63, YCBD is doing worse than 89.29% of the companies in the same industry.
YCBD has a Quick Ratio of 0.63. This is a bad value and indicates that YCBD is not financially healthy enough and could expect problems in meeting its short term obligations.
YCBD's Quick ratio of 0.36 is on the low side compared to the rest of the industry. YCBD is outperformed by 93.37% of its industry peers.
Industry RankSector Rank
Current Ratio 0.63
Quick Ratio 0.36
YCBD Yearly Current Assets VS Current LiabilitesYCBD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 71.77% over the past year.
The Revenue for YCBD has decreased by -19.35% in the past year. This is quite bad
YCBD shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -3.80% yearly.
EPS 1Y (TTM)71.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-132.81%
Revenue 1Y (TTM)-19.35%
Revenue growth 3Y-24.06%
Revenue growth 5Y-3.8%
Sales Q2Q%-10.96%

3.2 Future

The Earnings Per Share is expected to grow by 40.90% on average over the next years. This is a very strong growth
YCBD is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.98% yearly.
EPS Next Y92.04%
EPS Next 2Y40.9%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-2.84%
Revenue Next 2Y0.98%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
YCBD Yearly Revenue VS EstimatesYCBD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 10M 20M 30M 40M
YCBD Yearly EPS VS EstimatesYCBD Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2023 2024 2025 2026 0 -500 -1K -1.5K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for YCBD. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for YCBD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
YCBD Price Earnings VS Forward Price EarningsYCBD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
YCBD Per share dataYCBD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6

4.3 Compensation for Growth

A more expensive valuation may be justified as YCBD's earnings are expected to grow with 40.90% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.9%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for YCBD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CBDMD INC

NYSEARCA:YCBD (9/18/2025, 2:45:12 PM)

0.693

+0 (+0.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)12-16 2025-12-16/amc
Inst Owners0.52%
Inst Owner Change36.83%
Ins Owners1.71%
Ins Owner Change9.97%
Market Cap6.17M
Analysts82.86
Price Target2.04 (194.37%)
Short Float %1.15%
Short Ratio0.92
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)12.64%
Min EPS beat(2)-16.42%
Max EPS beat(2)41.71%
EPS beat(4)3
Avg EPS beat(4)44.78%
Min EPS beat(4)-16.42%
Max EPS beat(4)112.65%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-6.4%
Min Revenue beat(2)-9.45%
Max Revenue beat(2)-3.36%
Revenue beat(4)1
Avg Revenue beat(4)-4.22%
Min Revenue beat(4)-9.45%
Max Revenue beat(4)2.96%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-33.33%
PT rev (3m)-33.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)93.75%
EPS NY rev (1m)72.45%
EPS NY rev (3m)72.45%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-6.77%
Revenue NY rev (3m)-11.17%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.32
P/FCF N/A
P/OCF N/A
P/B 9.27
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-6.03
EYN/A
EPS(NY)-0.2
Fwd EYN/A
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS2.2
BVpS0.07
TBVpS-0.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -38.06%
ROE -625.23%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 62.35%
FCFM N/A
ROA(3y)-140.25%
ROA(5y)-86.1%
ROE(3y)-308.88%
ROE(5y)-187.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.98%
GM growth 5Y0.07%
F-Score4
Asset Turnover1.79
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 25%
Cap/Sales 1.48%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.63
Quick Ratio 0.36
Altman-Z -22.26
F-Score4
WACC9.68%
ROIC/WACCN/A
Cap/Depr(3y)26.48%
Cap/Depr(5y)59.22%
Cap/Sales(3y)1.56%
Cap/Sales(5y)1.72%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)71.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-132.81%
EPS Next Y92.04%
EPS Next 2Y40.9%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-19.35%
Revenue growth 3Y-24.06%
Revenue growth 5Y-3.8%
Sales Q2Q%-10.96%
Revenue Next Year-2.84%
Revenue Next 2Y0.98%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y80.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y95.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y99.38%
OCF growth 3YN/A
OCF growth 5YN/A